Bilcare Limited announced the completion of multiple corporate actions following its board meeting held on March 30, 2026. The pharmaceutical packaging company executed significant transactions involving preference share redemption, warrant conversion, and subsidiary liquidation as disclosed to BSE under Regulation 30.

Preference Share Redemption Worth ₹3.15 Crore

The company successfully redeemed 31.50 lakh preference shares of Caprihans India Limited on March 23, 2026. These 0.1% Non-Cumulative, Non-Participating Redeemable Preference Shares were valued at ₹10 each, aggregating to ₹3.15 crore. This redemption was part of Caprihans India Limited's exercise to redeem 2.80 crore preference shares from the total outstanding of 16.66 crore preference shares before March 31, 2026.

Warrant Conversion and Equity Share Allotment

Bilcare exercised its right to convert 12.90 lakh warrants into equity shares of Caprihans India Limited through multiple tranches. The company had initially invested in 48.00 lakh convertible warrants at ₹200 each in December 2024, with each warrant convertible into one equity share of ₹10 at ₹200 per share.

Through these conversions, Bilcare's shareholding in Caprihans India Limited increased from 55.99% to 59.56%, strengthening its position in the investee company.

Completion of UK Subsidiary Liquidation

The board reviewed and confirmed the successful completion of voluntary liquidation of Bilcare GCS Limited, a wholly owned subsidiary in the United Kingdom. The liquidation process, conducted under applicable laws of England & Wales, was completed on March 18, 2026.

The subsidiary's minimal contribution to the group's consolidated turnover reflects its non-material status. Liquidation proceeds of GBP 195,781.83 have been remitted by the liquidator and are awaiting credit to the company's account.

Regulatory Compliance and Board Meeting Details

The board meeting commenced at 16:15 PM IST and concluded at 17:10 PM IST on March 30, 2026. Company Secretary Sagar R. Baheti signed the regulatory disclosure to BSE, ensuring compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company has fulfilled all disclosure requirements under Regulation 30, providing comprehensive details of the corporate actions to stock exchanges with proper documentation and annexures.

Bilcare Limited announced its unaudited financial results for the quarter and nine months ended 31st December 2025, presenting a mixed performance picture with strong standalone results contrasted by consolidated operational challenges. The pharmaceutical packaging solutions company's Board of Directors approved these results during their meeting held on February 12, 2026.

Standalone Financial Performance Shows Strong Recovery

The company's standalone operations demonstrated remarkable improvement in profitability metrics during Q3FY26. Net profit surged to ₹2.71 crores compared to ₹1.80 crores in the corresponding quarter of the previous year, marking a significant 50.56% year-on-year growth.

For the nine-month period ended 31st December 2025, standalone performance remained robust with net profit of ₹7.34 crores against ₹0.63 crores in the previous year, representing an exceptional growth of over 1000%.

Consolidated Operations Face Headwinds

Contrasting the standalone success, consolidated operations continued to face significant challenges. The group reported a net loss of ₹12.81 crores in Q3FY26, though this represented an improvement from the ₹16.25 crores loss recorded in Q3FY25.

The nine-month consolidated results showed a net loss of ₹45.89 crores compared to ₹61.20 crores in the previous year, indicating gradual operational improvements despite ongoing challenges.

Strategic Corporate Actions and Regulatory Compliance

Bilcare announced two significant corporate decisions involving its subsidiary Caprihans India Limited (CIL). The company received intimation from CIL for redemption of 2,80,50,000 preference shares worth ₹10 each, representing a portion of the total outstanding preference shares. Additionally, Bilcare decided to exercise conversion rights for 18,70,000 convertible warrants into equity shares at a premium of ₹190 per share, requiring a payment of ₹28,05,00,000 in multiple tranches.

Labour Code Implementation Impact

The company addressed the financial implications of India's new Labour Codes notified on 21 November 2025. Bilcare assessed the incremental impact on employee benefits, disclosing ₹0.07 crores for gratuity and ₹0.01 crores for compensated absences as exceptional items. On a consolidated basis, the group reported ₹1.79 crores impact for gratuity and ₹0.01 crores for compensated absences, primarily arising from changes in wage definitions under the new regulatory framework.

Auditor Observations and Going Concern

The statutory auditors highlighted several key matters including the company's going concern status, ongoing SFIO investigations, and classification issues related to CSIR loan obligations. Despite past operating losses, the financial statements were prepared on a going concern basis considering positive prospects for the GCS business and management's strategic plans for future operations.